AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Remains Bullish on CareDx (CDNA) Following Presentation of AlloSure Performance
June 14, 2016 9:07 AM EDTPiper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
June 14, 2016 7:20 AM EDTMizuho Securities maintained a Buy rating on CareDx, Inc (NASDAQ: CDNA), and cut the price target to $8.00 (from $12.00) mainly due to share dilution from the Allenex acquisition. The deal transforms CDNA into a comprehensive transplant test provider, adding pre-transplant solutions, and increases the... More
